The Pfizer Clinical Research Unit is conducting a clinical trial of a study drug for atopic dermatitis. This study will look at the effects of the study drug when single oral doses are given to healthy volunteers with or without food.
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin conditions. It causes a rash and itching and can negatively affect patients’ emotional well-being. There is no cure for AD and while available treatments may provide symptom relief, the community needs new long-term treatment options.
Learn how you can support patients as a healthy volunteer below.
Who may participate
Healthy clinical trial participants are a critical part of early drug development and build the foundation for later phases of research.
This study is seeking healthy adult volunteers, meaning that the participants will not have the condition being studied and are in overall good health. In addition to the criteria listed, participants must meet the following requirements:
- Willing to take a study drug
- Willing and able to come to our facility in New Haven, CT*
- Willing and able to comply with all study procedures
*participants may be eligible to receive a bonus for travel, ask our staff for details
**females must be unable to bear children
There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Do you know someone who may meet these requirements? Refer a friend and you may be eligible to receive a bonus.
Condition
Healthy
Age
18-65 years
Sex
All sexes
Referral bonus
Up to $200
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in New Haven, CT. If you qualify for the study, there may be a period of up to 28 days before dosing.
If you choose to participate, you will stay at our facility up to 4 separate times for 8 nights each, for a total of up to 32 overnights. Each admission is about 2 weeks apart. On the morning after each admission, you will receive either a single oral dose of the study drug or a placebo, which has no active ingredient, up to a total of 4 doses. All of the doses will be provided as a liquid which you will swallow and may be provided with or without a meal.
About 2 weeks after the last dose, you will return to the PCRU for a follow-up visit (this does not involve staying overnight).
Throughout the study, staff will closely monitor your health status and collect data, such as the levels of the study drug in your blood.
*You may be asked to admit early for additional overnights during certain periods of the study. If this occurs, you will be compensated at a rate of $300 for each additional overnight.
Required overnight stays
Up to 32 overnights over 4 admissions
Long-term follow up
1 visit + 1 phone call
How long is this study?
About 86 days
Compensation
Up to $15,000 upon completion of the study
All of the study procedures will be clearly explained to you during screening and can be found in the the informed consent document (ICD). You may request a copy of the ICD prior to your scheduled screening if you would like additional time to review.
The PCRU Loyalty Program has arrived!
Our new Loyalty Program offers unique tiered gifts for new and returning participants.
Interested in participating?
Complete and submit this form, and a Pfizer New Haven Clinical Research Unit (PCRU) representative will contact you.
You may also call 1-800-254-6398 and speak with a PCRU representative to learn more.
For Japanese language assistance only, please call 1-833-711-9984.
The personal data gathered here will be collected, processed, and maintained in a confidential manner. Your information will be stored in our research unit’s database. We may use this information to invite you to participate in current and future clinical studies at the PCRU. You will have full access to your records at the Pfizer New Haven Clinical Research Unit and the opportunity to correct them if necessary.